These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15765996)

  • 1. [Coagulation tests during treatment with Drotrecogin alpha (activated): do results reflect the clinical situation?].
    Roca de Togores López A; Armero Ibáñez R; Seller Losada JM; Petusa Collado V; Onrubia Fuertes X; Sifre Julio C; Bellver Romero J; Barberá Alacreu M
    Rev Esp Anestesiol Reanim; 2005 Feb; 52(2):117-8. PubMed ID: 15765996
    [No Abstract]   [Full Text] [Related]  

  • 2. Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis.
    Pastores SM
    Postgrad Med J; 2003 Jan; 79(927):5-10. PubMed ID: 12566544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in treating patients with severe sepsis. Role of drotrecogin alfa (activated).
    Kleinpell R
    Crit Care Nurse; 2003 Jun; 23(3):16-29; quiz 67-8. PubMed ID: 12830777
    [No Abstract]   [Full Text] [Related]  

  • 4. An after action report of drotrecogin α (activated) and lessons for the future*.
    Wheeler DS
    Pediatr Crit Care Med; 2012 Nov; 13(6):692-4. PubMed ID: 23128590
    [No Abstract]   [Full Text] [Related]  

  • 5. [Questionable efficacy and safety of activated drotrecogin alpha (activated protein C) in the treatment of severe sepsis].
    Girbes AR; Polderman KH; Beishuizen A; van Zanten AR; Schultz MJ
    Ned Tijdschr Geneeskd; 2006 Jun; 150(22):1265-6; author reply 1266. PubMed ID: 16796179
    [No Abstract]   [Full Text] [Related]  

  • 6. Drotrecogin alfa (activated) in severe sepsis.
    LaRosa SP
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395833
    [No Abstract]   [Full Text] [Related]  

  • 7. Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated).
    McEvoy M
    Am J Crit Care; 2003 Sep; 12(5):398; author reply 398. PubMed ID: 14503421
    [No Abstract]   [Full Text] [Related]  

  • 8. Drotrecogin alfa (activated) administration: too many subgroups.
    Carlet J
    Crit Care Med; 2003 Oct; 31(10):2564; author reply 2564-5. PubMed ID: 14530774
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated).
    Critical Care Society of South Africa Working Group
    S Afr Med J; 2003 Jun; 93(6):416-7. PubMed ID: 12916374
    [No Abstract]   [Full Text] [Related]  

  • 10. Drotrecogin alfa (activated) in severe sepsis.
    Baillie JK; Murray G
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395834
    [No Abstract]   [Full Text] [Related]  

  • 11. Effectiveness of drotrecogin alfa (activated) in clinical practice: a stitch in time.
    Doig G
    Crit Care Med; 2008 Jan; 36(1):332-3. PubMed ID: 18158441
    [No Abstract]   [Full Text] [Related]  

  • 12. Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated).
    Morris PE
    Am J Crit Care; 2003 Mar; 12(2):94-7. PubMed ID: 12625165
    [No Abstract]   [Full Text] [Related]  

  • 13. Drotrecogin alfa (activated) in severe sepsis.
    Friedrich JO
    N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16394311
    [No Abstract]   [Full Text] [Related]  

  • 14. Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death.
    Friedrich JO; Adhikari NK; Meade MO
    Crit Care; 2006; 10(6):427. PubMed ID: 17214908
    [No Abstract]   [Full Text] [Related]  

  • 15. Drotrecogin alfa (activated) in South African private hospital ICUs.
    Hodgson RE; Williams PG; Foden AP; Grolman D
    S Afr Med J; 2003 Jul; 93(7):474-5. PubMed ID: 12939910
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of drotrecogin alfa recombinant activated protein C for severe sepsis in the critically burned patient: a new treatment approach.
    Weintraub J; Satterwhite T; Allo M
    Burns; 2006 Sep; 32(6):783-7. PubMed ID: 16879921
    [No Abstract]   [Full Text] [Related]  

  • 17. The development of drotrecogin alfa (activated) for the treatment of severe sepsis.
    Macias WL; Yan SB; Grinnell BW
    Int J Artif Organs; 2004 May; 27(5):360-70. PubMed ID: 15202813
    [No Abstract]   [Full Text] [Related]  

  • 18. Drotrecogin alpha (activated): the treatment for severe sepsis?
    Vincent JL
    Expert Opin Biol Ther; 2007 Nov; 7(11):1763-77. PubMed ID: 17961098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drotrecogin alfa (activated) falls amid continuing enthusiasm to normalise physiology in ICU patients.
    Shekar K; Fraser JF
    Crit Care Resusc; 2012 Dec; 14(4):324. PubMed ID: 23230883
    [No Abstract]   [Full Text] [Related]  

  • 20. Criteria for use of drotrecogin alfa.
    Mann HJ
    Am J Health Syst Pharm; 2004 Jan; 61(2):202; author reply 204-5. PubMed ID: 14750406
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.